# Elastrin Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/elastrin-therapeutics

- Industry: Biotechnology
- Headquarters: US
- Website: www.elastrin-therapeutics.com
- Total disclosed funding: $3.6M
- Latest round: Seed (Apr 7, 2022)
- Investors on record: 3

## About

Based in the US, Elastrin Therapeutics Inc. is a biotechnology company dedicated to developing innovative therapies for cardiovascular diseases, focusing on improving vascular health and restoring tissue elasticity.Elastrin Therapeutics Inc. specializes in creating biopharmaceutical products targeting cardiovascular health, aiming for significant advancements in patient care. Founded in 2017, the company has not undergone any major pivots in business strategy. The firm is headquartered in the US. The co-founders include Douglas Mulhall and Naren Vyavahare, while Matthias Breugelmans serves as the CEO. The company has successfully raised a total of USD 3.60 mn, primarily from a SEED funding round led by KIZOO Technology Ventures on April 7, 2022, which contributed to the total amount raised by the company.Elastrin Therapeutics Inc. develops therapies aimed at addressing the root causes of cardiovascular diseases. Their main products are advanced biopharmaceuticals designed to enhance vascular health and restore elasticity in cardiovascular tissues. These therapies are crucial for preventing and treating various heart conditions, including hypertension, heart failure, and atherosclerosis. Their target market includes healthcare providers, hospitals, and clinics focusing on cardiovascular care throughout North America and Europe.Elastrin Therapeutics operates through a transaction model driven by partnerships with healthcare institutions and direct sales to medical facilities. Their revenue generation strategy is facilitated by subscription agreements for ongoing access to their therapies, alongside collaborations with pharmaceutical companies for development and distribution. Transactions typically occur through B2B arrangements, providing healthcare providers access to the company's therapies, aligning with their objective to enhance patient outcomes in cardiovascular health.In April 2022, Elastrin Therapeutics Inc. secured USD 10 mn in venture funding, led by KIZOO Technology Ventures, with participation from South Carolina Research Authority and Starbloom Capital. The funds will be utilized to expand operations and boost development efforts. The company is focusing on launching new products aimed at improving cardiovascular treatment options, while also targeting expansion into North American and European markets by the end of 2023.

## Funding rounds

- Seed, Apr 7, 2022, $3.6M — South Carolina Research Authority, KIZOO Technology Ventures, Starbloom Capital
- Seed, Mar 3, 2021 — KIZOO Technology Ventures

## Investors

- KIZOO Technology Ventures (https://capitalatlas.ai/funds/kizoo-technology-ventures) — Seed
- South Carolina Research Authority — Seed
- Starbloom Capital (https://capitalatlas.ai/funds/starbloom-capital) — Seed